



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Vapendavir-d₅ Item No. 31320

CAS Registry No.: 2738376-73-1
Formal Name: 3-(ethoxy-d₅)-6-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-1,2-benzisoxazole
Synonym: BTA798-d₅
MF: C₂₁H₂₁D₅N₄O₃
FW: 387.5
Chemical Purity: ≥98% (Vapendavir)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₅); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vapendavir-d₅ is intended for use as an internal standard for the quantification of vapendavir (Item No. 30546) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Vapendavir-d₅ is supplied as a solid. A stock solution may be made by dissolving the vapendavir-d₅ in the solvent of choice, which should be purged with an inert gas. Vapendavir-d₅ is soluble in DMSO and methanol.

Description

Vapendavir is a capsid-binding antiviral agent.^{1,2} It binds to a pocket in the human rhinovirus (HRV) strain HRV2 VP1 capsid protein and inhibits the cytopathic effects of HRV2 and HRV14 in HeLa Ohio cells (EC₅₀s = 1 and 5 ng/ml, respectively), as well as in a panel of 39 HRV clinical isolates (median EC₅₀ = 7.3 ng/ml).¹ Vapendavir inhibits replication in a panel of 21 enterovirus 71 (EV71) isolates with an average EC₅₀ value of 0.7 μM.²

References

1. Feil, S.C., Hamilton, S., Krippner, G.Y., *et al.* An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. *ACS Med. Chem. Lett.* **3**(4), 303-307 (2012).
2. Tijsma, A., Franco, D., Tucker, S., *et al.* The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. *Antimicrob. Agents Chemother.* **58**(11), 6990-6992 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/26/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM